TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

(2012) Christina Bjerre et al.   ACTA ONCOLOGICA

Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases

(2012) Alessandro Neri et al.   HUMAN PATHOLOGY

Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway

(2011) Z.Y. Fu et al.   BIOMEDICINE & PHARMACOTHERAPY

Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients

(2011) T. N. Pathiraja et al.   CLINICAL CANCER RESEARCH

Role of fulvestrant in the management of postmenopausal breast cancer

(2011) Jonathan Krell et al.   Expert Review of Anticancer Therapy

KEGG for integration and interpretation of large-scale molecular data sets

(2011) M. Kanehisa et al.   NUCLEIC ACIDS RESEARCH

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

(2010) S. Ohno et al.   ANNALS OF ONCOLOGY

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

(2010) Kathleen I. Pritchard et al.   BREAST CANCER RESEARCH AND TREATMENT

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Reactome: a database of reactions, pathways and biological processes

(2010) D. Croft et al.   NUCLEIC ACIDS RESEARCH

NetPath: a public resource of curated signal transduction pathways

(2010) Kumaran Kandasamy et al.   GENOME BIOLOGY

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

(2009) Marie Klintman et al.   BREAST CANCER RESEARCH AND TREATMENT

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study

(2009) Gro L. Willemoe et al.   EUROPEAN JOURNAL OF CANCER

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

(2009) John F.R. Robertson et al.   JOURNAL OF CLINICAL ONCOLOGY

TIMP-1 as a tumor marker in breast cancer – An update

(2008) Sidse Ø Würtz et al.   ACTA ONCOLOGICA

TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro

(2008) Rebecca L. H. Bigelow et al.   BREAST CANCER RESEARCH AND TREATMENT

GEMS (Gene Expression Metasignatures), a Web Resource for Querying Meta-analysis of Expression Microarray Datasets: 17 -Estradiol in MCF-7 Cells

(2008) S. A. Ochsner et al.   CANCER RESEARCH

Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer

(2008) Allan Lipton et al.   JOURNAL OF CLINICAL ONCOLOGY

New insights into the classical and non-classical actions of estrogen: Evidence from estrogen receptor knock-out and knock-in mice

(2008) Melissa A. McDevitt et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks

(2008) A. P. Davis et al.   NUCLEIC ACIDS RESEARCH